PBS Biotech Closes $10 Million Funding Round
Stradling represented PBS Biotech, a leading manufacturer of single-use bioreactor systems, on its recent $10 million funding round with BroadOak Capital Partners. The financing will enable the company to expand and industrialize its portfolio of single-use bioreactor systems and contract process development services.
We are excited to have this business milestone accomplished at the perfect time. With the support of BroadOak, PBS Biotech will deliver on our vision of becoming the world’s standard manufacturing platform for allogeneic cell therapies, starting with a full line of GMP-qualified bioreactor systems to support the clinical studies and commercialization needs of our customers.
